Glaxo Avoids Market for Lemons by Acquiring Collaborators

Glaxo Avoids Market for Lemons by Acquiring Collaborators

Simon Dawson/Bloomberg

Glaxo this year has agreed to buy the 80 percent share of Cellzome it didn’t own, made a hostile bid for Human Genome Sciences Inc., and increased its stake in Theravance Inc.